These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20030567)

  • 1. Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
    Scranton R; Cincotta A
    Expert Opin Pharmacother; 2010 Feb; 11(2):269-79. PubMed ID: 20030567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine (Cycloset) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):97-8. PubMed ID: 21344781
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine mesylate (Cycloset) for type 2 diabetes mellitus.
    Weiland CM; Hilaire ML
    Am Fam Physician; 2013 May; 87(10):718-20. PubMed ID: 23939451
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.
    Roe ED; Chamarthi B; Raskin P
    J Diabetes Res; 2015; 2015():834903. PubMed ID: 26060825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quick-release bromocriptine for treatment of type 2 diabetes.
    Mikhail N
    Curr Drug Deliv; 2011 Sep; 8(5):511-6. PubMed ID: 21696353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
    Lamos EM; Levitt DL; Munir KM
    Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
    Chamarthi B; Gaziano JM; Blonde L; Vinik A; Scranton RE; Ezrokhi M; Rutty D; Cincotta AH
    J Diabetes Res; 2015; 2015():157698. PubMed ID: 26060823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive therapy of type 2 diabetes (ACCORD trial) (OCTOBER 2008).
    Najman DM
    Cleve Clin J Med; 2009 Feb; 76(2):83; author reply 83-4. PubMed ID: 19188472
    [No Abstract]   [Full Text] [Related]  

  • 10. Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
    Siamashvili M; Davis S
    Expert Opin Pharmacother; 2021 Feb; 22(2):241-247. PubMed ID: 33030357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
    Schwartz SS; Zangeneh F
    Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
    Owens D
    J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
    [No Abstract]   [Full Text] [Related]  

  • 13. An update on the long-acting insulin analogue glargine.
    Thisted H; Johnsen SP; Rungby J
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.
    Grunberger G
    J Diabetes; 2013 Jun; 5(2):110-7. PubMed ID: 23452312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Bromocriptine-QR as an Adjunctive Therapy on Glycemic Control in Subjects with Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
    Yanto TA; Budiputri CL; Muljono MP; Chandra S
    J ASEAN Fed Endocr Soc; 2024; 39(1):95-105. PubMed ID: 38863918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
    Chamarthi B; Ezrokhi M; Rutty D; Cincotta AH
    Postgrad Med; 2016 Nov; 128(8):761-769. PubMed ID: 27687032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR.
    Bell DS
    Postgrad Med; 2012 Sep; 124(5):121-35. PubMed ID: 23095432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical update on Humalog Mix25 a novel pre-mixed formulation of insulin lispro and NPL.
    Herz M
    Int J Clin Pract Suppl; 1999 Jul; 104():8-13; discussion 18-20. PubMed ID: 12669732
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.